

# Lauren Allen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9905022/publications.pdf>

Version: 2024-02-01

20  
papers

8,812  
citations

623188

14  
h-index

713013

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

14758  
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma. <i>Methods in Molecular Biology</i> , 2022, 2414, 341-362.	0.4	8
2	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
3	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
4	Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. <i>Nature Communications</i> , 2021, 12, 81.	5.8	141
5	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021, 12, 1260.	5.8	115
6	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
7	Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. <i>Nature Protocols</i> , 2021, 16, 3114-3140.	5.5	195
8	A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	7
9	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	2.0	15
10	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
11	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	4.7	20
12	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
13	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	6.3	519
14	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
15	Solid sorbitan esters nanoparticles are efficient and low-cost vehicles for subunit vaccines: Proof of concept with <i>Neisseria meningitidis</i> protein Mip. <i>Journal of Drug Delivery Science and Technology</i> , 2017, 42, 299-306.	1.4	1
16	Placental transfer of anti-group B <i>Streptococcus</i> immunoglobulin G antibody subclasses from HIV-infected and uninfected women to their uninfected infants. <i>Aids</i> , 2016, 30, 471-475.	1.0	17
17	Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against <i>Neisseria meningitidis</i> Serogroup B in England. <i>Vaccine Journal</i> , 2015, 22, 503-509.	3.2	7
18	Anti-Group B <i>Streptococcus</i> antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. <i>Vaccine</i> , 2015, 33, 621-627.	1.7	34

#	ARTICLE	IF	CITATIONS
19	Development of a large scale human complement source for use in bacterial immunoassays. <i>Journal of Immunological Methods</i> , 2013, 391, 39-49.	0.6	20
20	Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: An investigational vaccine component against <i>Neisseria meningitidis</i> . <i>Vaccine</i> , 2012, 30, 1330-1342.	1.7	10